Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab
In a paper published in Clinical Genitourinary Cancer the link [...]
ASCO 2020: Subtypes of kidney cancer differ in sites of metastases
A paper presented during the 2020 American Society of Clinical [...]
Bone metastases are associated with poor prognosis in papillary kidney cancer
A recent retrospective study looked at the data from 49 [...]
ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma
In a study presented during the 2020 American Society of [...]
Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating [...]
First-line immunotherapy combination treatments for metastatic kidney cancer
A meta-analysis of four major clinical trials of immunotherapy combinations [...]
Axitinib first-line treatment of papillary renal cell carcinoma
The majority of renal cell carcinomas (RCCs) are a subtype [...]
ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer
Surgery to remove the kidney tumour is often the preferred [...]
